4.6 Article

Effects of deep brain stimulation in dyskinetic cerebral palsy: A meta-analysis

Journal

MOVEMENT DISORDERS
Volume 28, Issue 5, Pages 647-654

Publisher

WILEY
DOI: 10.1002/mds.25339

Keywords

meta-analysis; deep brain stimulation; dyskinetic cerebral palsy

Funding

  1. Medtronic
  2. German Research Foundation (DFG)
  3. Walter- and Marga-Boll-StiftungPfizer
  4. Turner-Syndrom-Vereinigung Deutschland e.V.
  5. Medtronic Ltd.
  6. Medtronic Inc
  7. Boston Scientific
  8. Bayer Healthcare
  9. UCB Schwarz Pharma
  10. TEVA Pharma
  11. Lundbeck Pharma
  12. Bracco
  13. Gianni PR
  14. Medas Pharma
  15. Desitin Pharma
  16. Boehringer Ingelheim
  17. GlaxoSmithKline
  18. Eumecom
  19. Orion Pharma
  20. Cephalon
  21. Abott
  22. GE Medical
  23. German Research Foundation
  24. German Ministry of Education and Research
  25. Manfred und Ursula Muller Stiftung
  26. Kluh Stiftung
  27. Hoffnungsbaum e.V.
  28. NBIA DISORDERS SOCIETY USA
  29. Koln Fortune
  30. Deutsche Parkinson Vereinigung

Ask authors/readers for more resources

Secondary dystonia encompasses a heterogeneous group with different etiologies. Cerebral palsy is the most common cause. Pharmacological treatment is often unsatisfactory. There are only limited data on the therapeutic outcomes of deep brain stimulation in dyskinetic cerebral palsy. The published literature regarding deep brain stimulation and secondary dystonia was reviewed in a meta-analysis to reevaluate the effect on cerebral palsy. The Burke-Fahn-Marsden Dystonia Rating Scale movement score was chosen as the primary outcome measure. Outcome over time was evaluated and summarized by mixed-model repeated-measures analysis, paired Student t test, and Pearson's correlation coefficient. Twenty articles comprising 68 patients with cerebral palsy undergoing deep brain stimulation assessed by the Burke-Fahn-Marsden Dystonia Rating Scale were identified. Most articles were case reports reflecting great variability in the score and duration of follow-up. The mean Burke-Fahn-Marsden Dystonia Rating Scale movement score was 64.94 +/- 25.40 preoperatively and dropped to 50.5 +/- 26.77 postoperatively, with a mean improvement of 23.6% (P < .001) at a median follow-up of 12 months. The mean Burke-Fahn-Marsden Dystonia Rating Scale disability score was 18.54 +/- 6.15 preoperatively and 16.83 +/- 6.42 postoperatively, with a mean improvement of 9.2% (P < .001). There was a significant negative correlation between severity of dystonia and clinical outcome (P < .05). Deep brain stimulation can be an effective treatment option for dyskinetic cerebral palsy. In view of the heterogeneous data, a prospective study with a large cohort of patients in a standardized setting with a multidisciplinary approach would be helpful in further evaluating the role of deep brain stimulation in cerebral palsy. (c) 2013 Movement Disorder Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available